Sotera SHC · NASDAQ
$17.89 -1.00% (-$0.18)
Summary
56 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 13 USD is left as net profit.
What to watch
- The share price is above the Bulios Fair Price.
- Repaying its net debt would take 3.5 years of operating profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 31.5 USD for 1 USD of yearly profit. Over the last five years it was 75.4 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 7.3% a year over 5 years. Over the last 3 years it grew by 5.1% a year. For the next fiscal year analysts expect revenue to grow by 7.2%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 45 USD
- Sales and administration 18 USD
- Taxes and other 23 USD
- Net profit 13 USD
Net profit, industry median (Medical - Diagnostics & Research) 8.8 USD
Out of every 100 USD of revenue, 13 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 20.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 11
- Hold 0
- Sell 1
Today's price within the analysts' price targets
The average target of $20.5 is 15% above today's price. 92% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Service 86%
- Product 14%
By region
- UNITED STATES 54%
- Europe 20%
- CANADA 19%
- Other Geographical Areas 6.9%
Service brings in 86% of revenue. Product grew fastest, by 7.4% a year.
Segments in detail